Blast clearance after one week of corticosteroids correlates with outcome and genetics but does not justify adding a residual disease time point in acute lymphoblastic leukemia treatment

Leuk Lymphoma. 2021 Mar;62(3):752-754. doi: 10.1080/10428194.2020.1839659. Epub 2020 Oct 29.

Authors

Barbora Vakrmanova¹, Eva Fronkova^{1

2}, Jan Zuna^{1

2}, Iveta Janotova², Yahia Jabali³, Leona Rezkova Reznickova¹, Katerina Zdrahalova², Jan Trka^{1

2}, Jan Stary², Ondrej Hrusak^{1

2}, Ester Mejstrikova^{1

2}

Affiliations

¹ Department of Paediatric Haematology and Oncology, Charles University, Second Faculty of Medicine, CLIP, Prague, Czech Republic.
² Department of Paediatric Haematology and Oncology, Motol University Hospital, Prague, Czech Republic.
³ Hospital Ceske Budejovice, Czech Republic.

PMID: 33118409
DOI: 10.1080/10428194.2020.1839659

No abstract available

Publication types

Letter
Research Support, Non-U.S. Gov't

MeSH terms

Adrenal Cortex Hormones / therapeutic use
Humans
Neoplasm, Residual
Precursor Cell Lymphoblastic Leukemia-Lymphoma* / drug therapy
Precursor Cell Lymphoblastic Leukemia-Lymphoma* / genetics
Treatment Outcome

Substances

Adrenal Cortex Hormones